Abstract

Non-alcoholic fatty liver disease (NAFLD) has reached epidemic proportions, affecting an estimated one-quarter of the world’s adult population. Multiple organ systems have been implicated in the pathophysiology of NAFLD; however, the role of skeletal muscle has until recently been largely overlooked. A growing body of evidence places skeletal muscle—via its impact on insulin resistance and systemic inflammation—and the muscle-liver axis at the center of the NAFLD pathogenic cascade. Population-based studies suggest that sarcopenia is an effect-modifier across the NAFLD spectrum in that it is tightly linked to an increased risk of non-alcoholic fatty liver, non-alcoholic steatohepatitis (NASH), and advanced liver fibrosis, all independent of obesity and insulin resistance. Longitudinal studies suggest that increases in skeletal muscle mass over time may both reduce the incidence of NAFLD and improve preexisting NAFLD. Adverse muscle composition, comprising both low muscle volume and high muscle fat infiltration (myosteatosis), is highly prevalent in patients with NAFLD. The risk of functional disability conferred by low muscle volume in NAFLD is further exacerbated by the presence of myosteatosis, which is twice as common in NAFLD as in other chronic liver diseases. Crosstalk between muscle and liver is influenced by several factors, including obesity, physical inactivity, ectopic fat deposition, oxidative stress, and proinflammatory mediators. In this perspective review, we discuss key pathophysiological processes driving sarcopenia in NAFLD: anabolic resistance, insulin resistance, metabolic inflexibility and systemic inflammation. Interventions that modify muscle quantity (mass), muscle quality (fat), and physical function by simultaneously engaging multiple targets and pathways implicated in muscle-liver crosstalk may be required to address the multifactorial pathogenesis of NAFLD/NASH and provide effective and durable therapies.

Highlights

  • Tremendous progress has been made in our understanding of the mechanisms underlying non-alcoholic fatty liver disease (NAFLD) [1,2,3], including the identification of several molecular pathways impacting a number of cell types and organ systems, ranging from the liver to adipose tissue, the gut, immune system, and kidney [4, 5]

  • Multiple factors have been delineated in the pathogenesis of NAFLD/Nonalcoholic steatohepatitis (NASH), including immune regulation, lipolysis, leaky gut and bile acid homeostasis, among others

  • There is close overlap between the pathophysiology of sarcopenia and NASH. This makes it challenging to determine whether sarcopenia is a risk factor for NASH, or if it is a complication of NASH, as the presence of either one may increase the risk for the other

Read more

Summary

INTRODUCTION

Tremendous progress has been made in our understanding of the mechanisms underlying non-alcoholic fatty liver disease (NAFLD) [1,2,3], including the identification of several molecular pathways impacting a number of cell types (hepatocytes, macrophages, stellate cells) and organ systems, ranging from the liver to adipose tissue, the gut, immune system, and kidney [4, 5]. Subjects in the highest tertile of change in SMI over 1 year showed the greatest reductions in BMI, alanine aminotransferase and aspartate aminotransferase, fasting glucose, homeostatic model assessment of insulin resistance, lipid parameters, and hepatic steatosis index score [49] These findings suggest that increases in skeletal muscle mass over time may slow, halt, or reverse NAFLD development and facilitate resolution of existing NAFLD. Observational Korean Sarcopenic Obesity cohort study of 452 apparently healthy adults [25], individuals with lower skeletal muscle mass (as measured by DXA to estimate SMI) exhibited increased risk of NAFLD (defined by the liver attenuation index measured using abdominal CT). There was a strong graded response with disease severity for NASH and fibrosis stage, both independent of obesity [52, 55]

A Few Limitations of Current Clinical Evidence
SUMMARY AND FUTURE DIRECTIONS
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call